What the FDA labels say about taking them together
Colchicine and cyclosporine
Colchicine's FDA label of July 22, 2025 names cyclosporine in its drug interactions section, and cyclosporine's label names colchicine too. The colchicine label: “Significant increase in colchicine plasma levels is anticipated with P-gp inhibitors.”
Check it at the source: the colchicine FDA label on DailyMed (effective July 22, 2025, Aurobindo Pharma Limited); the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation).
What does the colchicine label say about cyclosporine?
Colchicine label, drug interactionsNamed in a table that the FDA label file prints without its column breaks; the full label shows the table.
Colchicine label, warnings and precautionsConcomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, gemfibrozil, fenofibrate, fenofibric acid or benzafibrate (themselves associated with myotoxicity) or cyclosporine with colchicine may potentiate the development of myopathy [see Drug Interactions (7) ].
Lodoco label (AGEPHA Pharma USA, LLC, August 13, 2026), drug interactionsDrug class: P- glycoprotein Inhibitors † cyclosporine ranolazine; Outcome/effect: Significant increase in colchicine plasma levels is anticipated with P-gp inhibitors.; Clinical comment: Concomitant use of LODOCO with strong P-gp inhibitors is contraindicated [see Contraindications (4)].
Lodoco label (AGEPHA Pharma USA, LLC, August 13, 2026), warnings and precautionsConcomitant use of LODOCO and HMG CoA reductase inhibitors, gemfibrozil, and fenofibric acid or cyclosporine may potentiate the development of myopathy [see Drug interactions (7)].
Gloperba label (Scilex Pharmaceuticals Inc., November 1, 2024), drug interactionsToxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., grapefruit juice, erythromycin, verapamil), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosporine).
Source: FDA drug label (Lodoco, NDA215727), AGEPHA Pharma USA, LLC, effective August 13, 2026 (SPL set ff06d68f-d65f-d097-e053-6294a90a7e5f), via openFDA
Source: FDA drug label (Colchicine), Aurobindo Pharma Limited, effective July 22, 2025 (SPL set dd93a40f-92ab-47ac-9083-b8a7a0b18ad6), via openFDA; the full label on DailyMed
What does the cyclosporine label say about colchicine?
Cyclosporine label, drug interactionsgentamicin; ketoconazole; colchicine; ranitidine; methotrexate
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Colchicine | Cyclosporine | |
|---|---|---|
| Labeled for | Gout | Organ transplant rejection, Rheumatoid arthritis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.122 per tablet 0.6 mg tablet | $1.04 per unit 0.05% eye emulsion |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once